Verastem, Inc.

Verastem, Inc.

7.70
USD
-0.48
(-5.87%)
-1.86EPS
760.48MMarket Cap
Mar 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
4.94
2.81
6.93
0.14
0.16
- -
0.28
0.45
1.05
Basic EPS, GAAP
-21.8
-24.82
-19.32
-11.82
-21.18
-13.38
-24.01
-5.3
-4.9
-4.57
-3.96
-3.66
-3.02
-1.87
Free Cash Flow per Basic Share
-13.95
-18.29
-15.29
-9.58
-17.9
-18.11
-22.29
-2.62
-3.69
-3.95
-3.92
-2.93
-2.12
-1.68
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
55.64
39.08
33.29
23.45
13.63
20.21
1.07
8.12
5.67
2.84
2.27
-0.65
0.74
0.11
Tangible Book Value per Share
55.64
39.08
33.29
23.45
13.63
16.7
-1.92
8.12
5.67
2.84
2.27
-0.65
0.52
-0.06
Basic Weighted Avg Shares
2
2
3
3
3
5
6
13
15
16
22
36
69
96
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
27
17
89
2
3
- -
10
31
100
Operating Margin (%)
- -
- -
- -
- -
- -
-354.75
-758.14
-55.76
-2,991.18
-2,809.59
- -
-1,149.56
-550.33
-193.73
Depreciation Expense
- -
- -
1
1
1
1
2
1
- -
- -
- -
- -
1
1
Net Income, GAAP
-41
-53
-58
-36
-68
-72
-149
-68
-71
-74
-87
-131
-209
-179
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-271.11
-854.77
-76.51
-3,468.1
-2,843.3
- -
-1,306.37
-677.59
-178.38
Working Capital
94
86
101
70
71
216
55
128
87
71
117
64
151
96
LT Debt
- -
- -
- -
- -
15
115
107
22
3
26
41
41
81
116
Total Equity
117
89
102
72
58
124
7
115
88
47
57
-29
57
10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-39.63
-51.76
-60.52
-41.7
-104.33
-79.61
-226.98
-110.62
-70.21
-109.39
-166.79
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
6
12
LT Borrowings
77
76
114
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
90
94
Market Capitalization
466
346
760

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
203
176
199
Cash, Cash Equivalents & STI
182
136
173
Accounts Receivable, Net
10
29
10
Inventories
2
2
2
Total Current Liabilities
67
78
103
Payables & Accruals
53
66
82
ST Debt
6
6
12
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
98.12%
-99.43%
-297.96%
Free Cash Flow
27.13%
35.22%
40.4%
Net Income, GAAP
24.43%
27.41%
60.35%
Sales/Revenue/Turnover
- -
- -
209.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
10
- -
- -
10
2025
- -
2
11
18
31
2026
19
40
24
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.26
-0.31
-0.6
-1.33
-3.66
2025
-0.96
-0.39
-1.35
-0.39
-3.02
2026
-0.37
-0.35
-0.74
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Daniel W. Paterson
Full Time Employees
102
Sector
Health technology
Industry
Biotechnology
Address
117 Kendrick Street Needham MA United States 02494
IPO Date
Jan 27, 2012
Business
Verastem, Inc. Verastem, Inc. (VSTM) is a late-stage biopharmaceutical company focused on developing and commercializing novel small molecule drugs targeting the RAS/MAPK signaling pathway in cancer, including RAF/MEK inhibition via avutometinib, FAK inhibition via defactinib, and KRAS G12D inhibition via VS-7375; the company advances these assets in monotherapy and combinations for low-grade serous ovarian cancer (LGSOC), pancreatic cancer, non-small cell lung cancer, colorectal cancer, and other RAS/MAPK-driven solid tumors, supported by investigator-sponsored trials and combinations with agents such as paclitaxel, pegylated liposomal doxorubicin, letrozole, anastrozole, and cetuximab. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global development strategy through partnerships, employing approximately 78 people under CEO Daniel Paterson. In recent developments, the U.S. FDA approved the avutometinib plus defactinib combination (AVMAPKI FAKZYNJA) as the first therapy for adult patients with KRAS-mutant recurrent LGSOC, with commercialization underway following a planned mid-2025 launch; the company refinanced debt with Oberland Capital, entered a strategic commercialization partnership with IQVIA, completed a $75 million private placement, advanced the GenFleet Therapeutics collaboration with Phase 1/2 initiation of VS-7375 (GFH375) in July 2024 after Chinese IND approval in June 2024, and outlined 2025 priorities including RAMP trials and pipeline expansion.

Company News

  • Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance

  • Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path

  • Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

  • What Verastem (VSTM) Said on Its Q3 Earnings Call

  • Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript

  • Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates

  • Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

  • Verastem Oncology to Participate in Upcoming November Investor Conferences

  • Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

  • Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

  • Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

  • Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

  • Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug

  • Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

  • Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

  • VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

  • Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

  • Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

  • Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research